Wednesday, July 8, 2026

Patent intelligence · US

US 9834513

Benzylamine derivatives

granted A61PA61P1/00A61P1/18A61P11/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 11
Applicant portfolio 24
Patent details — US 9834513
Jurisdiction
US
Status
granted
Grant date
Dec 5, 2017
Expiration
Nov 30, 2037
Claims
26
CPC classes
A61P, A61P1/00, A61P1/18, A61P11/00
View on Google Patents ↗

Quick answer

US 9834513 (Benzylamine derivatives) is held by KalVista Pharmaceuticals Limited. Status: granted. Granted Dec 5, 2017. Expires Nov 30, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
26
CPC classes
A61P, A61P1/00, A61P1/18, A61P11/00, A61P13/12, A61P19/02

More from KalVista Pharmaceuticals Limited

Related pharmaceutical patents in our USPTO index.

  1. US 11739068

    Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof

    KalVista Pharmaceuticals Limited · Expires Aug 24, 2043

    granted
  2. US 11613527

    Enzyme inhibitors

    KalVista Pharmaceuticals Limited · Expires Mar 23, 2043

    granted
  3. US 11584735

    Solid forms of a plasma kallikrein inhibitor and salts thereof

    KalVista Pharmaceuticals Limited · Expires Feb 16, 2043

    granted
  4. US 11242333

    Inhibitors of plasma kallikrein

    KalVista Pharmaceuticals Limited · Expires Feb 3, 2042

    granted
  5. US 11234939

    Dosage forms comprising a plasma kallikrein inhibitor

    KalVista Pharmaceuticals Limited · Expires Jan 27, 2042

    granted
  6. US 11230537

    Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors

    KalVista Pharmaceuticals Limited · Expires Jan 20, 2042

    granted
  7. US 11198691

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Expires Dec 9, 2041

    granted
  8. US 11180484

    Pyrazole derivatives as plasma kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Expires Nov 18, 2041

    granted

Frequently asked questions

What is US patent 9834513?

US 9834513 (Benzylamine derivatives) is held by KalVista Pharmaceuticals Limited. Status: granted. Granted Dec 5, 2017. Expires Nov 30, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9834513?

KalVista Pharmaceuticals Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.

When does US 9834513 expire?

Our index shows an expiration date of Nov 30, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.